GoodRx to restate first-half 2026 financials over understated revenue
GDRX•GoodRx Holdings deemed its first- and second-quarter 2026 financial statements unreliable because Pharma Direct revenue was understated. Expected restatements would raise first-half revenue by $29.77 million to $424.19 million and net income by $14.85 million to $24.55 million.
1. Financial statements unreliable
GoodRx Holdings said on October 27, 2026, that its first- and second-quarter financial statements were unreliable because of understated Pharma Direct revenue. The revenue recognition errors violated ASC 606 requirements, and the company plans to amend its Forms 10-Q for the affected periods.
2. Expected adjustments
The restatements are expected to increase first-half total revenue by $29.77 million to $424.19 million and net income by $14.85 million to $24.55 million. GoodRx expects one or more material weaknesses in internal control over financial reporting for both quarters.
